Intravenous Magnesium in Patients Receiving Cisplatin

Inclusion Criteria: * Adults ≥18 years with malignant mesothelioma admitted for HIOCC. Because no dosing or adverse event data are currently available on the use of intravenous magnesium participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric studies. * Glomerular filtration rate (GFR)≥ 30 ml/min/1.73m2 at the time of enrollment * Patients must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients with a pre-treatment serum Magnesium level \>2.5 mg/dl or \<1.3 mg/dl at the preoperative visit * Patients with AKI at the time of enrollment, assessed by Kidney Disease Improving Outcomes Criteria (serum creatinine increase ≥1.5x baseline) * Patients with estimated glomerular filtration rate \<30 ml/min/1.73m2 at the time of enrollment * Patients with neuromuscular disease (e.g., amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, myositis) * Patients with sustained bradycardia (heart rate \<50 beats per minute on 1 or more EKGs in the preceding 90 days) or 2nd degree AV heart block type 2 or higher with the absence of a functioning pacemaker * Participants who are receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to intravenous magnesium * Participants with uncontrolled intercurrent illness. * Participants with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because they may need magnesium for treatment of preeclampsia or eclampsia, apart from this study.